AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00827762 — intervention group
Intervention type: DRUG
Intervention: Kuvan
Description: 20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study NCT01032382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
Description: topical application to CL lesions once daily for 20 days
Study NCT01032382 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paromomycin Alone Cream (15% paromomycin topical cream)
Description: topical application to CL lesions once daily for 20 days
Study NCT04553068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVO100
Description: EVO100 vaginal gel
Study NCT04553068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal gel
Study NCT04410250 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: oral hygiene
Description: Mothers will be instructed on the oral hygiene of the newborn
Study NCT04410250 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: oral hygiene
Description: Mothers will be instructed on the oral hygiene of the newborn
Study NCT01922479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: 1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
Study NCT01922479 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
Study NCT01723813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2
Description: Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
Study NCT01723813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galectin-3 inhibitor: GM-CT-01 systemic injections
Description: Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
Study NCT01723813 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration
Description: GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
Study NCT01881581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution is used as control in all arms.
Study NCT01881581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: D-GPEi
Description: D-GPEi is used in Arm A,B,C,G and H.
Study NCT01881581 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-GPE
Description: M-GPE is used in Arm D,E,F,G and H
Study NCT00937833 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostatectomy
Study NCT00937833 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Study NCT00937833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgisis Male Sling
Study NCT03099317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sinew acupuncture
Description: Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
Study NCT03099317 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
Study NCT01822522 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT01822522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01822522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01629784 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cutaneous Lupus educational script
Description: Subjects will listen to a short informational script on Cutaneous lupus and skin protection
Study NCT01292798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
Study NCT00410397 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Medicine
Description: Pelvic balancing, myofascial release of the anterior pelvis.
Study NCT00410397 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham Manipulation
Description: Neutral positional, gentle palpation
Study NCT00772213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIGTS treatment
Description: treatment of multiple trauma patients in the MIGTS
Study NCT03712189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeFlow
Description: The LifeFlow® is a hand-operated rapid infuser designed to administer fluids to patients by a single user, for clinical situations in which a large volume or rapid infusion of fluid or colloid is required. The device delivers fluid in 10mL increments with each complete handle compression, which refills during release, automating a push-pull mechanism. The syringe then automatically refills with handle release.
Study NCT00615238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus continuous bouts
Description: Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
Study NCT00615238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus short bouts
Description: Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
Study NCT00615238 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet plus moderate lifestyle activity
Description: Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
Study NCT00995007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474 (Vandetanib)
Description: Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
Study NCT00995007 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
Study NCT01744353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 1
Description: Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Study NCT01744353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 2/MTD
Description: Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Study NCT01744353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 3
Description: Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
Study NCT02370680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: steady-state run-in prior to Durlaza treatment
Study NCT02370680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durlaza™
Description: comparison of different numbers of capsules
Study NCT02066051 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IPL
Description: Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
Study NCT02066051 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meibomian Gland Expression
Description: After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
Study NCT01170546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plate-loaded kneeling leg curl with internal rotation
Description: The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
Study NCT01170546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plate-loaded squat press
Description: The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
Study NCT01170546 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plate-loaded kneeling leg curl
Description: An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
Study NCT06473376 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: arthrocentesis
Description: TMJ arthrocentesis and arthroscopy
Study NCT00959972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
Study NCT00959972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine Patch
Description: Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
Study NCT00662350 — intervention group
Intervention type: DEVICE
Intervention: The Wallterm™ System
Description: The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
Study NCT01788267 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scan examination HR-pQCT
Study NCT01686360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Study NCT00565383 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Description: Combined spinal-epidural
Study NCT00565383 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous fentanyl (50mcg)
Description: Intravenous fentanyl
Study NCT01831830 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Veterans' In-home Program
Description: VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
Study NCT04600479 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Evaluation of the prevalence of HCV, HBV and HIV viral infections
Description: 1. Assessment of prevalence HCV, HBV and HIV prevalence estimations. Sociodemographic and clinical data will be collected from the patient's medical record and through self-questionnaires completed by the patient. A systematic screening by 3 RDTs (HCV, HBV and HIV) will be proposed in the specific framework of the SaPHIR study.This is a screening performed on capillary blood (TOYO VHC ®, TOYO VHB ® and INSTI HIV 1 / HIV 2 ®), to obtain a result in less than 30 minutes.~   In case of confirmation of the diagnosis of viral hepatitis or HIV infection, the final result will be transmitted and explained to the patient by the referring doctor, who will organize the adapted care pathway and prescribe the DAA for the simple patients. The complex patients will be referred to the specialist to consider starting an appropriate treatment.~2. Evaluation of care pathway and barriers to care for hepatitis C. Only patients with positive HCV RDT participating in this follow-up.
Study NCT03270332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: inhalation of 270μg albuterol through a spacer
Study NCT03270332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inhalation of placebo through a spacer
Study NCT00486876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextofisopam
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
Study NCT00486876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextofisopam
Description: capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
Study NCT00980681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotarem
Description: Each subject will receive one injection of Dotarem 0.2ml/kg
Study NCT00980681 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Time of Flight
Description: Each subject will undergo a TOF MRA
Study NCT01615380 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT+ Contact
Description: In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
Study NCT01615380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT+ Exercise
Description: Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
Study NCT03951779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise cardiac magnetic resonance imaging
Description: Subjects will exercise on a treadmill and immediately following the completion of the stress protocol, subjects will undergo cardiac magnetic resonance imaging
Study NCT02679339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNTX-2022 (lidocaine gel, 40%)
Study NCT02679339 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00390611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Study NCT00390611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel
Study NCT00390611 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin
Study NCT04435379 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VPM1002
Description: The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Study NCT04435379 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The investigational product will be administered via intradermal injection with a 1.0-ml syringe, sub-graduated into hundredths of ml (1/100 ml), and fitted with a short bevel needle (25G/0.50 mm or 26G/0.45 mm, 10 mm in length).
Study NCT04190433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Given PO
Study NCT04190433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Given PO
Study NCT04190433 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Given PO
Study NCT04190433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Given PO
Study NCT04190433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: Given PO
Study NCT04190433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Given PO
Study NCT01317225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17 α hydroxyprogesterone caproate
Description: 250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
Study NCT01317225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
Study NCT03675776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapastinel
Description: Rapastinel (prefilled syringe, weekly intravenous IV administration).
Study NCT03675776 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (prefilled syringe, weekly IV administration).
Study NCT02031939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy, Chemoradiotherapy and gap chemotherapy (Capecitabine combine with oxaliplatin)
Description: All rectal cancer patients in this group will receive induction, gap chemotherapy (capecitabine combined with oxaliplatin) alone with chemoradiotherapy (capecitabine combine with oxaliplatin) before surgery.
Study NCT02031939 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: standard chemoradiotherapy
Description: All rectal patients in this group will receive standard radiotherapy and surgical resection.
Study NCT04567667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] BMS-986278
Description: Specified dose on specified days
Study NCT04567667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kinevac®
Description: Specified dose on specified days
Study NCT02537938 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGP 555
Study NCT01494350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WR 279,396 topical cream
Description: WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
Study NCT02608879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oral Mucosa Deterging and Periodontal Debridement (OMDP)
Description: OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
Study NCT02608879 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard of Care Oral Hygiene Instructions
Description: Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
Study NCT02608879 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental scaling, ultrasonic
Description: An ultrasonic dental scaler will be used to clean the teeth
Study NCT02608879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Non-alcoholic chlorhexidine will be used as part of the OMDP protocol